

Anal Cancer - Pipeline Insight, 2021

<https://marketpublishers.com/r/ADD3C675BB1BEN.html>

Date: March 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: ADD3C675BB1BEN

Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight's, "Anal Cancer - Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Anal Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Anal Cancer Understanding

Anal Cancer: Overview

Anal cancer is a rare condition, although its incidence has been increasing over the past several decades, particularly in women. The majority of anal cancers are squamous cell cancers and are linked with human papilloma virus (HPV) infection. Many anal cancers are found early because they are in a location that your physician can easily see and reach. Diagnosis is often made when people with any of the above symptoms undergo an anal exam. Anal cancer may also be found incidentally during yearly physical exams that include a digital rectal exam. The rectal exam is performed to check the rectum, prostate or other pelvic organs. Anal cancers can also be found when a person has a preventive colorectal screening test (such as a colonoscopy).

'Anal Cancer - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive

insights of present scenario and growth prospects across the indication. A detailed picture of the Anal Cancer pipeline landscape is provided which includes the disease overview and Anal Cancer treatment guidelines. The assessment part of the report embraces, in depth Anal Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Anal Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Anal Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Anal Cancer.

Anal Cancer Emerging Drugs Chapters

This segment of the Anal Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Anal Cancer Emerging Drugs

Atezolizumab: Genentech

Atezolizumab blocks the interaction of PD-L1 with programmed cell death protein 1 (PD-1) and CD80 receptors (B7-1Rs).[16] PD-L1 can be highly expressed on certain tumors, which is thought to lead to reduced activation of immune cells (cytotoxic T-cells in particular) that might otherwise recognize and attack the cancer.[16] Inhibition of PD-L1 by atezolizumab can remove this inhibitor effect and thereby engender an anti-tumor response. The drug is in phase 2 of clinical trials for the treatment of anal cancer,

Avelumab: Merck KGaA

Avelumab is a human anti-programmed death ligand-1 (PD-L1) antibody. Avelumab has been shown in preclinical models to engage both the adaptive and innate immune functions. By blocking the interaction of PD-L1 with PD-1 receptors, avelumab has been shown to release the suppression of the T cell-mediated antitumor immune response in preclinical models. The drug is in phase I/II of clinical trials for the treatment of anal cancer.

Further product details are provided in the report.....

Anal Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Anal Cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Anal Cancer

There are approx. 5+ key companies which are developing the therapies for Anal Cancer. The companies which have their Anal Cancer drug candidates in the mid to advanced stage, i.e. phase II include, Genentech.

Phases

DelveInsight's report covers around 5+ products under different phases of clinical development like

Late-stage products (phase III)

Mid-stage products (Phase II and Phase I/II)

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Anal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Subcutaneous

Intravenous

Oral

Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

Small molecules

Natural metabolites

Monoclonal antibodies

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Anal Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Anal Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Anal Cancer drugs.

Anal Cancer Report Insights

Anal Cancer Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Anal Cancer Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Anal Cancer drugs?

How many Anal Cancer drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Anal Cancer?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Anal Cancer therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Anal Cancer and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Genentech

Merck KGaA

Inovio Pharmaceuticals

Key Products

Atezolizumab

Avelumab

VGX 3100

Contents

Introduction

Executive Summary

Anal Cancer: Overview

- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management

Pipeline Therapeutics

- Comparative Analysis

Therapeutic Assessment

- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type

Anal Cancer – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

- Anal Cancer companies' collaborations, Licensing, Acquisition -Deal Value Trends

Anal Cancer Collaboration Deals

- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

- Comparative Analysis

Ceftobiprole medocaril: Basilea pharmaceutica

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

- Comparative Analysis

Drug name: Company name

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

- Comparative Analysis

Anal Cancer Key Companies

Anal Cancer Key Products

Anal Cancer- Unmet Needs

Anal Cancer- Market Drivers and Barriers

Anal Cancer- Future Perspectives and Conclusion

Anal Cancer Analyst Views

Anal Cancer Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Anal Cancer

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Anal Cancer
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Anal Cancer - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/ADD3C675BB1BEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/ADD3C675BB1BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970